Kura Oncology (NASDAQ:KURA) Sets New 1-Year Low – Time to Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA) hit a new 52-week low during trading on Tuesday . The stock traded as low as $8.34 and last traded at $8.56, with a volume of 96391 shares traded. The stock had previously closed at $8.51.

Analyst Ratings Changes

Several equities analysts recently commented on KURA shares. Bank of America dropped their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. UBS Group assumed coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.86.

Kura Oncology Stock Performance

The firm has a 50-day simple moving average of $12.29 and a two-hundred day simple moving average of $17.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $650.88 million, a price-to-earnings ratio of -3.55 and a beta of 0.81.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC bought a new position in Kura Oncology during the third quarter valued at about $25,000. Point72 DIFC Ltd acquired a new stake in Kura Oncology in the 3rd quarter worth approximately $146,000. Quarry LP bought a new stake in shares of Kura Oncology during the 2nd quarter worth $196,000. Erste Asset Management GmbH acquired a new position in shares of Kura Oncology during the third quarter valued at about $215,000. Finally, Bellevue Group AG grew its holdings in shares of Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.